Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Strong Trading Volume – Here’s What Happened

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) saw an uptick in trading volume on Monday . 2,223,671 shares were traded during mid-day trading, an increase of 82% from the previous session’s volume of 1,224,552 shares.The stock last traded at $12.1235 and had previously closed at $12.02.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on BAYRY. Zacks Research cut shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 24th. DZ Bank upgraded Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 9th. Barclays upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. Finally, UBS Group upgraded Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research note on Monday, March 16th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Bayer Aktiengesellschaft presently has an average rating of “Moderate Buy”.

Bayer Aktiengesellschaft Stock Up 0.9%

The company has a current ratio of 1.01, a quick ratio of 0.63 and a debt-to-equity ratio of 1.22. The firm has a market cap of $47.67 billion, a P/E ratio of -10.93 and a beta of 0.70. The stock’s fifty day moving average is $11.89 and its two-hundred day moving average is $10.61.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings results on Wednesday, March 4th. The company reported $0.18 EPS for the quarter, meeting the consensus estimate of $0.18. The firm had revenue of $13.24 billion during the quarter, compared to the consensus estimate of $13.08 billion. Bayer Aktiengesellschaft had a negative net margin of 8.51% and a positive return on equity of 15.93%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. As a group, research analysts anticipate that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.